Covered recipient · General Payments record
CHERYL A HULL
Allopathic & Osteopathic Physicians Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2020 · Entire year
$231.11
11 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2020 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $231.11 | 11 |
By paying entity
PY2020 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Ortho Dermatologics, a division of Bausch Health US, LLC | $89.31 | 1 |
| Allergan, Inc. | $49.35 | 3 |
| Galderma Laboratories, L.P. | $37.53 | 3 |
| AbbVie Inc. | $24.13 | 2 |
| GENZYME CORPORATION | $16.06 | 1 |
| Janssen Biotech, Inc. | $14.73 | 1 |
Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
CHERYL A HULL
NPI 1124081849 · CMS profile ID 142103
Allopathic & Osteopathic Physicians / Dermatology
ROGERS, AR
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1124081849?year=2020&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- CHERYL A HULL, NPI 1124081849, CMS profile ID 142103. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1124081849?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- APA 7
- IndustryPayments. (2026). CHERYL A HULL, NPI 1124081849, CMS profile ID 142103. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1124081849?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- Bluebook
- CHERYL A HULL, NPI 1124081849, CMS profile ID 142103, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1124081849?year=2020&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2020
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30
11 matching records · $231.11 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–11 of 11.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Janssen Biotech, Inc. | $14.73 | 12/11/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 753377775 | CMS |
| GENZYME CORPORATION | $16.06 | 12/09/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744206425 | CMS |
| AbbVie Inc. | $12.53 | 10/29/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721890423 | CMS |
| Galderma Laboratories, L.P. | $12.51 | 10/12/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 726853687 | CMS |
| Allergan, Inc. | $14.78 | 09/23/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 723718299 | CMS |
| AbbVie Inc. | $11.60 | 09/11/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721890419 | CMS |
| Allergan, Inc. | $12.65 | 08/26/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 723718297 | CMS |
| Galderma Laboratories, L.P. | $12.31 | 08/24/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 726853683 | CMS |
| Galderma Laboratories, L.P. | $12.71 | 03/11/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 726853681 | CMS |
| Allergan, Inc. | $21.92 | 01/29/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 723718295 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $89.31 | 01/15/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 737464623 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $380,038.55 | 259 |
| PY2024 | Principal investigator | $408,860.46 | 382 |
| PY2023 | Principal investigator | $228,849.11 | 170 |
| PY2022 | Recipient | $321.00 | 1 |
| PY2022 | Principal investigator | $248,165.36 | 66 |
| PY2021 | Recipient | $2,700.00 | 2 |
| PY2021 | Principal investigator | $244,500.15 | 37 |
| PY2020 | Recipient | $643.47 | 2 |
| PY2020 | Principal investigator | $251,307.20 | 46 |
| PY2019 | Recipient | $4.75 | 1 |
| PY2019 | Principal investigator | $990,287.65 | 92 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
93 records in PY2019
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | AbbVie, Inc. | $1,567.80 | 12/30/2019 | Non-covered Recipient Entity Northwest Arkansas Clinical Trials Center PLLC | M15-997 | No dispute reported | 06/30/2026 | 647606259 |
| Principal investigator 1 | Bausch Health US, LLC | $9,729.00 | 12/20/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CENTER | MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, 2-ARM, PARALLEL GROUP EFFICACYSAFETY STUDY | No dispute reported | 06/30/2026 | 684366893 |
| Principal investigator 1 | AbbVie, Inc. | $669.40 | 12/19/2019 | Non-covered Recipient Entity Northwest Arkansas Clinical Trials Center PLLC | M15-999 | No dispute reported | 06/30/2026 | 647606255 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $132.50 | 12/01/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CTR PLLC | Phase IIa study in patients with atopic dermatitis | No dispute reported | 06/30/2026 | 708445971 |
| Principal investigator 1 | AbbVie, Inc. | $1,533.00 | 11/27/2019 | Non-covered Recipient Entity Northwest Arkansas Clinical Trials Center PLLC | M15-997 | No dispute reported | 06/30/2026 | 647606261 |
| Principal investigator 1 | Amgen Inc. | $4,137.60 | 11/25/2019 | Non-covered Recipient Entity HULL DERMATOLOGY & AESTHETICS - NORTHWEST ARKANSAS CLINICAL TRIALS CENTER | A Study of the Efficacy and Safety of Apremilast CC-10004 in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp STYLE | No dispute reported | 06/30/2026 | 675786111 |
| Principal investigator 1 | Bausch Health US, LLC | $16,045.00 | 11/25/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CENTER | MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, 2-ARM, PARALLEL GROUP EFFICACYSAFETY STUDY | No dispute reported | 06/30/2026 | 684366405 |
| Principal investigator 1 | AbbVie, Inc. | $4,038.60 | 11/21/2019 | Non-covered Recipient Entity Northwest Arkansas Clinical Trials Center PLLC | M15-999 | No dispute reported | 06/30/2026 | 647606253 |
| Principal investigator 1 | Bausch Health US, LLC | $14,496.00 | 11/18/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CENTER | MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, 2-ARM, PARALLEL GROUP EFFICACYSAFETY STUDY | No dispute reported | 06/30/2026 | 684366131 |
| Principal investigator 1 | AbbVie, Inc. | $1,567.80 | 11/14/2019 | Non-covered Recipient Entity Northwest Arkansas Clinical Trials Center PLLC | M15-997 | No dispute reported | 06/30/2026 | 647606263 |
| Principal investigator 1 | PFIZER INC. | $600.00 | 11/13/2019 | Non-covered Recipient Entity NW ARKANSAS CLINICAL TRIALS CTR PLLC | A PHASE 2A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY WITH AN EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF06651600 AND PF06700841 IN SUBJECTS WITH MODERATE TO SEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 671667019 |
| Principal investigator 1 | Bausch Health US, LLC | $5,917.00 | 11/09/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIAL CENTER | A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, 2 ARM, PARALLEL GROUP STUDY COMPARING THE SAFETY AND EFFICACY OF IDP-123 LOTION AND IDP-123 VEHICLE LOTION IN THE TREATMENT OF ACNE VULGARIS | No dispute reported | 06/30/2026 | 684366053 |
| Principal investigator 1 | Incyte Corporation | $3,285.90 | 11/06/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CENTER | A Double Blind, Randomized, Dose Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo | No dispute reported | 06/30/2026 | 666476623 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $132.50 | 11/01/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CTR PLLC | Phase IIa study in patients with atopic dermatitis | No dispute reported | 06/30/2026 | 708445969 |
| Principal investigator 1 | AbbVie, Inc. | $1,075.60 | 10/21/2019 | Non-covered Recipient Entity Northwest Arkansas Clinical Trials Center PLLC | M15-999 | No dispute reported | 06/30/2026 | 647606247 |
| Principal investigator 1 | AbbVie, Inc. | $1,066.20 | 10/15/2019 | Non-covered Recipient Entity Northwest Arkansas Clinical Trials Center PLLC | M15-997 | No dispute reported | 06/30/2026 | 647606257 |
| Principal investigator 1 | Bausch Health US, LLC | $1,797.00 | 10/09/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CENTER | MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, 2-ARM, PARALLEL GROUP EFFICACYSAFETY STUDY | No dispute reported | 06/30/2026 | 684365520 |
| Principal investigator 1 | Bausch Health US, LLC | $8,290.00 | 10/09/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CENTER | MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, 2-ARM, PARALLEL GROUP EFFICACYSAFETY STUDY | No dispute reported | 06/30/2026 | 684365525 |
| Principal investigator 1 | AbbVie, Inc. | $2,580.00 | 10/02/2019 | Non-covered Recipient Entity HULL DERMATOLOGY P.A. | P10-023 | No dispute reported | 06/30/2026 | 647606237 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $132.50 | 10/01/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CTR PLLC | Phase IIa study in patients with atopic dermatitis | No dispute reported | 06/30/2026 | 708445967 |
| Principal investigator 1 | AbbVie, Inc. | $2,452.80 | 09/26/2019 | Non-covered Recipient Entity Northwest Arkansas Clinical Trials Center PLLC | M15-997 | No dispute reported | 06/30/2026 | 647606251 |
| Principal investigator 1 | Bausch Health US, LLC | $8,548.00 | 09/10/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CENTER | MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, 2-ARM, PARALLEL GROUP EFFICACYSAFETY STUDY | No dispute reported | 06/30/2026 | 684365161 |
| Principal investigator 1 | Incyte Corporation | $30.40 | 09/10/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CENTER | A Double Blind, Randomized, Dose Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo | No dispute reported | 06/30/2026 | 666476615 |
| Principal investigator 1 | Incyte Corporation | $28.65 | 09/10/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CENTER | A Double Blind, Randomized, Dose Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo | No dispute reported | 06/30/2026 | 666476617 |
| Principal investigator 1 | Incyte Corporation | $23.40 | 09/10/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CENTER | A Double Blind, Randomized, Dose Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo | No dispute reported | 06/30/2026 | 666476619 |
| Principal investigator 1 | Incyte Corporation | $23.40 | 09/10/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CENTER | A Double Blind, Randomized, Dose Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo | No dispute reported | 06/30/2026 | 666476621 |
| Principal investigator 1 | Incyte Corporation | $2,937.60 | 09/04/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CENTER | A Double Blind, Randomized, Dose Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo | No dispute reported | 06/30/2026 | 666476609 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $132.50 | 09/01/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CTR PLLC | Phase IIa study in patients with atopic dermatitis | No dispute reported | 06/30/2026 | 708445891 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,884.60 | 08/29/2019 | Non-covered Recipient Entity Nw Arkansas Clnc Trials Ctr Pllc | A multicenter open registry of patients with psoriasis who are candidates for systematic therapy including biologics | No dispute reported | 06/30/2026 | 654254529 |
| Principal investigator 1 | AbbVie, Inc. | $1,567.80 | 08/28/2019 | Non-covered Recipient Entity Northwest Arkansas Clinical Trials Center PLLC | M15-997 | No dispute reported | 06/30/2026 | 647606249 |
| Principal investigator 1 | Aclaris Therapeutics, Inc. | $70.00 | 08/20/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CENTER | A RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ATI-502 TOPICAL SOLUTION ADMINISTERED TWICE-DAILY FOR 28 DAYS IN ADULT SUBJECTS WITH ALOPECIA UNIVERSALIS AND ALOPECIA TOTALIS WITH A 6-MONTH LONG-TERM OPEN-LABEL EXTENSION | No dispute reported | 06/30/2026 | 700989791 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $8,100.00 | 08/20/2019 | Non-covered Recipient Entity Northwest Arkansas Clinical Trials | Phase IIa study in patients with atopic dermatitis | No dispute reported | 06/30/2026 | 704144191 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $132.50 | 08/01/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CTR PLLC | Phase IIa study in patients with atopic dermatitis | No dispute reported | 06/30/2026 | 708445869 |
| Principal investigator 1 | Bausch Health US, LLC | $3,884.00 | 07/29/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CENTER | MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, 2-ARM, PARALLEL GROUP EFFICACYSAFETY STUDY | No dispute reported | 06/30/2026 | 684364511 |
| Principal investigator 1 | AbbVie, Inc. | $1,533.00 | 07/26/2019 | Non-covered Recipient Entity Northwest Arkansas Clinical Trials Center PLLC | M15-997 | No dispute reported | 06/30/2026 | 647606243 |
| Principal investigator 1 | AbbVie, Inc. | $2,097.60 | 07/25/2019 | Non-covered Recipient Entity Northwest Arkansas Clinical Trials Center PLLC | M15-997 | No dispute reported | 06/30/2026 | 647606245 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $1.25 | 07/25/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CTR PLLC | Phase IIa study in patients with atopic dermatitis | No dispute reported | 06/30/2026 | 703550517 |
| Principal investigator 1 | Aclaris Therapeutics, Inc. | $1,450.00 | 07/23/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CENTER | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF ATI-501 ORAL SUSPENSION COMPARED TO PLACEBO IN ADULT SUBJECTS WITH ALOPECIA AREATA, ALOPECIA UNIVERSALIS OR ALOPECIA TOTALIS | No dispute reported | 06/30/2026 | 700989249 |
| Principal investigator 1 | Dr.Reddy's Laboratories,Inc. | $359.30 | 07/09/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC | Randomized,Doube-Blind, Placebo-Controlled, Multicenter, 24 week study to assess the Efficacy and Safety of PPC-06, extended release tablets in Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 701425919 |
| Principal investigator 1 | Dr.Reddy's Laboratories,Inc. | $4,272.00 | 07/02/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC | Randomized,Doube-Blind, Placebo-Controlled, Multicenter, 24 week study to assess the Efficacy and Safety of PPC-06, extended release tablets in Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 701425915 |
| Principal investigator 1 | Dr.Reddy's Laboratories,Inc. | $250.00 | 07/02/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC | Randomized,Doube-Blind, Placebo-Controlled, Multicenter, 24 week study to assess the Efficacy and Safety of PPC-06, extended release tablets in Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 701425917 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $132.50 | 07/01/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CTR PLLC | Phase IIa study in patients with atopic dermatitis | No dispute reported | 06/30/2026 | 708446013 |
| Principal investigator 1 | Incyte Corporation | $2,937.60 | 07/01/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CENTER | A Double Blind, Randomized, Dose Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo | No dispute reported | 06/30/2026 | 666476607 |
| Principal investigator 1 | Bausch Health US, LLC | $6,398.00 | 06/28/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CENTER | MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, 2-ARM, PARALLEL GROUP EFFICACYSAFETY STUDY | No dispute reported | 06/30/2026 | 684364091 |
| Principal investigator 1 | AbbVie, Inc. | $1,567.80 | 06/27/2019 | Non-covered Recipient Entity Northwest Arkansas Clinical Trials Center PLLC | M15-997 | No dispute reported | 06/30/2026 | 647606241 |
| Principal investigator 1 | Eli Lilly and Company | $1,299.12 | 06/25/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 654292279 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $6.71 | 06/18/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CTR PLLC | Phase IIa study in patients with atopic dermatitis | No dispute reported | 06/30/2026 | 703550353 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $132.50 | 06/01/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CTR PLLC | Phase IIa study in patients with atopic dermatitis | No dispute reported | 06/30/2026 | 708446031 |
| Principal investigator 1 | Bausch Health US, LLC | $4,481.00 | 05/31/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CENTER | MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, 2-ARM, PARALLEL GROUP EFFICACYSAFETY STUDY | No dispute reported | 06/30/2026 | 684363803 |
| Principal investigator 1 | Bausch Health US, LLC | $6,375.00 | 05/30/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CENTER | MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, 2-ARM, PARALLEL GROUP EFFICACYSAFETY STUDY | No dispute reported | 06/30/2026 | 684363707 |
| Principal investigator 1 | AbbVie, Inc. | $1,066.20 | 05/29/2019 | Non-covered Recipient Entity Northwest Arkansas Clinical Trials Center PLLC | M15-997 | No dispute reported | 06/30/2026 | 647606239 |
| Recipient | Eli Lilly and Company | $4.75 | 05/29/2019 | Covered Recipient Physician | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 654281915 |
| Principal investigator 1 | Aclaris Therapeutics, Inc. | $150.00 | 05/28/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CENTER | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF ATI-501 ORAL SUSPENSION COMPARED TO PLACEBO IN ADULT SUBJECTS WITH ALOPECIA AREATA, ALOPECIA UNIVERSALIS OR ALOPECIA TOTALIS | No dispute reported | 06/30/2026 | 700988645 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,245.60 | 05/23/2019 | Non-covered Recipient Entity Nw Arkansas Clnc Trials Ctr Pllc | A multicenter open registry of patients with psoriasis who are candidates for systematic therapy including biologics | No dispute reported | 06/30/2026 | 654254527 |
| Principal investigator 1 | Celgene Corporation | $500.00 | 05/09/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIAL | A Phase 3, Multi-Center, Randomized, Place-Controlled, Double-Blind, Study of the Efficacy and Safety of Apremilast (CC-10004 in subjects with Moderate to Sever Plaque Psoriasis of the Scap) (CC-10004-SPSO-001) | No dispute reported | 06/30/2026 | 675418165 |
| Principal investigator 1 | Aclaris Therapeutics, Inc. | $2,000.00 | 05/07/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CENTER | A RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ATI-502 TOPICAL SOLUTION ADMINISTERED TWICE-DAILY FOR 28 DAYS IN ADULT SUBJECTS WITH ALOPECIA UNIVERSALIS AND ALOPECIA TOTALIS WITH A 6-MONTH LONG-TERM OPEN-LABEL EXTENSION | No dispute reported | 06/30/2026 | 700988301 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $132.50 | 05/01/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CTR PLLC | Phase IIa study in patients with atopic dermatitis | No dispute reported | 06/30/2026 | 708445917 |
| Principal investigator 1 | Aclaris Therapeutics, Inc. | $775.00 | 04/25/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CENTER | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF ATI-501 ORAL SUSPENSION COMPARED TO PLACEBO IN ADULT SUBJECTS WITH ALOPECIA AREATA, ALOPECIA UNIVERSALIS OR ALOPECIA TOTALIS | No dispute reported | 06/30/2026 | 700988037 |
| Principal investigator 1 | Celgene Corporation | $730.51 | 04/23/2019 | Non-covered Recipient Entity Hull Dermatology & Aesthetics - Northwest Arkansas Clinical Trials Center | A PHASE 3, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, STUDY OF THE EFFICACY AND SAFETY Of APREMILAST (CC-10004), COMPARED TO PLACEBO, IN SUBJECTS WTIH MILD TO MODERATE PLAQUE PSORIASIS (CC-10004-PSOR-022) | No dispute reported | 06/30/2026 | 675417393 |
| Principal investigator 1 | Celgene Corporation | $41,796.30 | 04/18/2019 | Non-covered Recipient Entity Hull Dermatology & Aesthetics - Northwest Arkansas Clinical Trials Center | A PHASE 3, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, STUDY OF THE EFFICACY AND SAFETY Of APREMILAST (CC-10004), COMPARED TO PLACEBO, IN SUBJECTS WTIH MILD TO MODERATE PLAQUE PSORIASIS (CC-10004-PSOR-022) | No dispute reported | 06/30/2026 | 675417391 |
| Principal investigator 1 | Aclaris Therapeutics, Inc. | $2,500.00 | 04/11/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CENTER | A RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ATI-502 TOPICAL SOLUTION ADMINISTERED TWICE-DAILY FOR 28 DAYS IN ADULT SUBJECTS WITH ALOPECIA UNIVERSALIS AND ALOPECIA TOTALIS WITH A 6-MONTH LONG-TERM OPEN-LABEL EXTENSION | No dispute reported | 06/30/2026 | 700987897 |
| Principal investigator 1 | Incyte Corporation | $23.40 | 04/08/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CENTER | A Double Blind, Randomized, Dose Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo | No dispute reported | 06/30/2026 | 666476601 |
| Principal investigator 1 | Incyte Corporation | $19.10 | 04/08/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CENTER | A Double Blind, Randomized, Dose Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo | No dispute reported | 06/30/2026 | 666476603 |
| Principal investigator 1 | Incyte Corporation | $23.40 | 04/08/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CENTER | A Double Blind, Randomized, Dose Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo | No dispute reported | 06/30/2026 | 666476605 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $132.50 | 04/01/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CTR PLLC | Phase IIa study in patients with atopic dermatitis | No dispute reported | 06/30/2026 | 708446051 |
| Principal investigator 1 | AbbVie, Inc. | $2,097.60 | 03/29/2019 | Non-covered Recipient Entity Northwest Arkansas Clinical Trials Center PLLC | M15-997 | No dispute reported | 06/30/2026 | 647606267 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $1,361.59 | 03/26/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CTR PLLC | Phase IIa study in patients with atopic dermatitis | No dispute reported | 06/30/2026 | 703550337 |
| Principal investigator 1 | Aclaris Therapeutics, Inc. | $985.00 | 03/19/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CENTER | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF ATI-501 ORAL SUSPENSION COMPARED TO PLACEBO IN ADULT SUBJECTS WITH ALOPECIA AREATA, ALOPECIA UNIVERSALIS OR ALOPECIA TOTALIS | No dispute reported | 06/30/2026 | 700987711 |
| Principal investigator 1 | Incyte Corporation | $1,395.00 | 03/08/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CENTER | A Double Blind, Randomized, Dose Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo | No dispute reported | 06/30/2026 | 666476595 |
| Principal investigator 1 | Aclaris Therapeutics, Inc. | $1,205.00 | 03/05/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CENTER | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF ATI-501 ORAL SUSPENSION COMPARED TO PLACEBO IN ADULT SUBJECTS WITH ALOPECIA AREATA, ALOPECIA UNIVERSALIS OR ALOPECIA TOTALIS | No dispute reported | 06/30/2026 | 700987431 |
| Principal investigator 1 | Incyte Corporation | $4,420.80 | 03/02/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CENTER | A Double Blind, Randomized, Dose Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo | No dispute reported | 06/30/2026 | 666476593 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $132.50 | 03/01/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CTR PLLC | Phase IIa study in patients with atopic dermatitis | No dispute reported | 06/30/2026 | 708445935 |
| Principal investigator 1 | Dr.Reddy's Laboratories,Inc. | $702.00 | 03/01/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC | Randomized,Doube-Blind, Placebo-Controlled, Multicenter, 24 week study to assess the Efficacy and Safety of PPC-06, extended release tablets in Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 701425953 |
| Principal investigator 1 | AbbVie, Inc. | $1,567.80 | 02/28/2019 | Non-covered Recipient Entity Northwest Arkansas Clinical Trials Center PLLC | M15-997 | No dispute reported | 06/30/2026 | 647606265 |
| Principal investigator 1 | Janssen Research & Development, LLC | $617.40 | 02/22/2019 | Non-covered Recipient Entity Nw Arkansas Clnc Trials Ctr Pllc | A multicenter open registry of patients with psoriasis who are candidates for systematic therapy including biologics | No dispute reported | 06/30/2026 | 654254531 |
| Principal investigator 1 | Bausch Health US, LLC | $3,339.00 | 02/21/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC | MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, 2-ARM, PARALLEL GROUP EFFICACYSAFETY STUDY | No dispute reported | 06/30/2026 | 684348745 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $108.73 | 02/19/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CTR PLLC | Phase IIa study in patients with atopic dermatitis | No dispute reported | 06/30/2026 | 703550067 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $248.96 | 02/15/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CTR PLLC | Phase IIa study in patients with atopic dermatitis | No dispute reported | 06/30/2026 | 703550074 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $17,191.50 | 02/15/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC | A RANDOMIZED DOUBLE BLIND MULTI CENTER STUDY ASSESSING SHORT 16 WEEKS AND LONG TERM EFFICACY UP TO 1 YEAR SAFETY AND TOLERABILITY OF 2 SUBCUTANEOUS SECUKINUMAB DOSE REGIMENS IN ADULT PATIENTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA SUNSHINE | No dispute reported | 06/30/2026 | 640722511 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $65.00 | 02/12/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CTR PLLC | Phase IIa study in patients with atopic dermatitis | No dispute reported | 06/30/2026 | 708446065 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $303.23 | 02/08/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CTR PLLC | Phase IIa study in patients with atopic dermatitis | No dispute reported | 06/30/2026 | 703550077 |
| Principal investigator 1 | Incyte Corporation | $5,672.70 | 02/07/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CENTER | A Double Blind, Randomized, Dose Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo | No dispute reported | 06/30/2026 | 666476589 |
| Principal investigator 1 | Incyte Corporation | $500.00 | 02/07/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CENTER | A Double Blind, Randomized, Dose Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo | No dispute reported | 06/30/2026 | 666476591 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $3,155.88 | 02/04/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CTR PLLC | Phase IIa study in patients with atopic dermatitis | No dispute reported | 06/30/2026 | 704733723 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $132.50 | 02/01/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CTR PLLC | Phase IIa study in patients with atopic dermatitis | No dispute reported | 06/30/2026 | 708446079 |
| Principal investigator 1 | AbbVie, Inc. | $1,533.00 | 01/28/2019 | Non-covered Recipient Entity Northwest Arkansas Clinical Trials Center PLLC | M15-997 | No dispute reported | 06/30/2026 | 647606269 |
| Principal investigator 1 | Incyte Corporation | $61.84 | 01/28/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CENTER | A Double Blind, Randomized, Dose Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo | No dispute reported | 06/30/2026 | 666476571 |
| Principal investigator 1 | Aclaris Therapeutics, Inc. | $195.00 | 01/22/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CENTER | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF ATI-501 ORAL SUSPENSION COMPARED TO PLACEBO IN ADULT SUBJECTS WITH ALOPECIA AREATA, ALOPECIA UNIVERSALIS OR ALOPECIA TOTALIS | No dispute reported | 06/30/2026 | 700986743 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,604.40 | 01/17/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CTR PLLC | Phase IIa study in patients with atopic dermatitis | No dispute reported | 06/30/2026 | 704143969 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $43,779.84 | 01/15/2019 | Non-covered Recipient Entity Dr Cheryl Hull | A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to Severe Psoriasis | No dispute reported | 06/30/2026 | 639760995 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $701,247.84 | 01/07/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC | A RANDOMIZED DOUBLE BLIND MULTICENTER STUDY ASSESSING SHORT 16 WEEKS AND LONG TERM EFFICACY UP TO 1 YEAR SAFETY AND TOLERABILITY OF SUBCUTANEOUS SECUKINUMAB IN SUBJECTS OF BODY WEIGHT 90 KG OR HIGHER WITH MODERATE TO SEVERE CHRONIC PLAQUE TYPE PSORIASIS | No dispute reported | 06/30/2026 | 640722515 |
| Principal investigator 1 | Incyte Corporation | $1,134.90 | 01/04/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CENTER | A Double Blind, Randomized, Dose Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo | No dispute reported | 06/30/2026 | 666476587 |
| Principal investigator 1 | Dr.Reddy's Laboratories,Inc. | $2,531.70 | 01/02/2019 | Non-covered Recipient Entity NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC | Randomized,Doube-Blind, Placebo-Controlled, Multicenter, 24 week study to assess the Efficacy and Safety of PPC-06, extended release tablets in Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 701425939 |